Generate Biomedicines initiated with an Overweight at Morgan Stanley

Morgan Stanley analyst Sean Laaman initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $20 price target The firm says its investment thesis is centered on GB-0895, the company’s AI-engineered, long-acting anti-TSLP monoclonal antibody in Phase 3 for severe asthma with a parallel development path in COPD. Generate also has two emerging oncology programs, GB-4362 and GB-5267, the analyst tells investors in a research note. Morgan Stanley says that these assets “provide early but potentially compelling validation” of Generate’s AI-first discovery platform.